Effect of CSF1R inhibitor on glial cells population and remyelination in the cuprizone model.
Aminopyridines
/ pharmacology
Animals
Cuprizone
Disease Models, Animal
Male
Mice
Mice, Inbred C57BL
Multiple Sclerosis
/ pathology
Myelin Sheath
/ drug effects
Neuroglia
/ drug effects
Pyrroles
/ pharmacology
Receptor, Macrophage Colony-Stimulating Factor
/ antagonists & inhibitors
Remyelination
/ drug effects
Astrocyte
Microglia
Multiple sclerosis
Oligodendrocyte
PLX3397
Journal
Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
15
03
2021
revised:
05
07
2021
accepted:
05
07
2021
pubmed:
19
7
2021
medline:
27
1
2022
entrez:
18
7
2021
Statut:
ppublish
Résumé
Multiple sclerosis is a kind of autoimmune and demyelinating disease with pathological symptoms such as inflammation, myelin loss, astrocytosis, and microgliosis. The colony stimulating factor 1 receptor (CSF1R) is an essential factor for the microglial function, and PLX3397 (PLX) is its specific inhibitor. In this wstudy, we assessed the effect of different doses of PLX for microglial ablation on glial cell population and remyelination process. Sixty male C57BL/6 mice (8 weeks old) were divided into 6 groups. The animals were fed with 0.2% cuprizone diet for 12 weeks. For microglial ablation, PLX (290 mg/kg) was added to the animal food for 3, 7, 14 and 21 days. Glial cell population was measured using immunohistochemistry. The rate of remyelination was evaluated using electron microscopy and Luxol Fast Blue staining. The expression levels of all genes were assessed by qRT-PCR method. Data were analysed using GraphPad Prism and SPSS software. The results showed that the administration of different doses of PLX significantly reduced microglial cells (p ≤ .001). PLX administration also significantly increased oligodendrocytes population (p ≤ .001) and remyelination compared to the cuprizone mice, which was aligned with the results of LFB and TEM. Gene results showed that PLX treatment reduced CSF1R expression. According to the results, the administration of PLX for 21 days enhanced remyelination by increasing oligodendrocytes in the chronic demyelination model. These positive effects could be related to the reduction of microglia.
Identifiants
pubmed: 34274854
pii: S0143-4179(21)00065-2
doi: 10.1016/j.npep.2021.102179
pii:
doi:
Substances chimiques
Aminopyridines
0
Pyrroles
0
Cuprizone
5N16U7E0AO
pexidartinib
6783M2LV5X
Receptor, Macrophage Colony-Stimulating Factor
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102179Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.